Karim Fizazi, MD, PhD - Clinical Trial Investigator | Syfrah

Trials Sponsors Conditions Drugs Pricing

Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(13)

DRUG(8)

OTHER(2)

unicancer, astrazeneca

radiation therapy

Cancer Type ID test

gustave-roussy-cancer-campus-grand-paris

+14 more interventions

22 unique interventions3 categories

Analytics

Trial Phases

Phase 36

Trial Status

Completed5

Recruiting1

Role Distribution

Principal Investigator2

Other Roles4

PI Rate33%

Activity Timeline

Clinical Trials (6)

NCT06625970Phase 3Recruiting

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

High Risk Prostate CarcinomaProstate Cancer

StudychairStart date: 2025-04-10

NCT02044354Phase 3Completed

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

StudychairStart date: 2014-05-22

NCT01540058Phase 3Completed

Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP

Neoplasms, Unknown Primary

PrincipalinvestigatorStart date: 2012-03-22

NCT00104676Phase 3Completed

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Extragonadal Germ Cell TumorTeratomaTesticular Germ Cell Tumor

StudychairStart date: 2003-11-26

NCT00055731Phase 3Completed

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Prostate Cancer

StudychairStart date: 2002-11-14

NCT00617669Phase 3Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

Prostate Cancer

Principalinvestigator

Research Network

Collaboration Network

4 collaborators·4 connections

Network Legend

KOL

Current Investigator

CO

High-influence Collaborator

CO

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Prostate Cancer3 Extragonadal Germ Cell Tumor1 High Risk Prostate Carcinoma1 Metastatic Castration-resistant Prostate Cancer1 Neoplasms, Unknown Primary1 Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).1 Teratoma1 Testicular Germ Cell Tumor1

Affiliations

Gustave Roussy, Cancer Campus, Grand Paris

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Pierre BLANCHARD, MD, PhD

Gustave Roussy, Cancer Campus, Grand Paris

Moderately Similar

Shared therapeutic areas:

High Risk Prostate CarcinomaPatients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).Prostate Cancer

Worked with same sponsors:

Collaborated on 1 trial

Similarity Score34%

Gilles CREHANGE, MD, PhD

Institut Curie

Moderately Similar

Shared therapeutic areas:

High Risk Prostate CarcinomaPatients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).Prostate Cancer

Worked with same sponsors:

Collaborated on 1 trial

Similarity Score34%

Judd W Moul, MD, FACS

Duke University

Shared therapeutic areas:

Prostate Cancer

Worked with same sponsors:

Collaborated on 1 trial

Similarity Score14%

Robert J. Motzer, MD

Memorial Sloan Kettering Cancer Center

Shared therapeutic areas:

Testicular Germ Cell TumorExtragonadal Germ Cell TumorTeratoma

Similarity Score11%

Zhaohui Zhu, MD

Peking Union Medical College Hospital

Shared therapeutic areas:

Prostate CancerMetastatic Castration-resistant Prostate Cancer

Similarity Score8%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Shared therapeutic areas:

Neoplasms, Unknown PrimaryProstate Cancer

Worked with same sponsors:

AstraZenecaBayer

Similarity Score8%

Rahul Aggarwal, MD

University of California, San Francisco

Shared therapeutic areas:

Prostate CancerMetastatic Castration-resistant Prostate Cancer

Worked with same sponsors:

AstraZenecaSanofi

Similarity Score8%

James L Gulley, M.D.

National Cancer Institute (NCI)

Shared therapeutic areas:

Prostate CancerMetastatic Castration-resistant Prostate Cancer

Similarity Score8%

Kevin Volpp, MD, PhD

University of Pennsylvania

Shared therapeutic areas:

Prostate Cancer

Similarity Score4%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Shared therapeutic areas:

Prostate Cancer

Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT06625970Phase 3StudyChair

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

High Risk Prostate CarcinomaProstate Cancer

Recruiting

NCT02044354Phase 3StudyChair

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Completed

NCT01540058Phase 3PrincipalInvestigator

Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP

Neoplasms, Unknown Primary

Completed

NCT00104676Phase 3StudyChair

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Extragonadal Germ Cell TumorTeratomaTesticular Germ Cell Tumor

Completed

NCT00055731Phase 3StudyChair

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Prostate Cancer

Completed

NCT00617669Phase 3PrincipalInvestigator

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

Prostate Cancer

Completed

All 6 trials loaded